[
  {
    "ts": "2025-10-29T23:00:00+00:00",
    "headline": "Apple & Amazon earnings, Fed, mortgage rates: What to Watch",
    "summary": "Market Domination Overtime host Josh Lipton previews several of the biggest stories to come tomorrow, Thursday, October 30, including earnings results from Big Tech names Apple (AAPL) and Amazon (AMZN), commentary from the Federal Reserve's Michelle Bowman, and the latest mortgage rates reading. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Domination Overtime.",
    "url": "https://finance.yahoo.com/video/apple-amazon-earnings-fed-mortgage-230000928.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "6b01c7dd-5955-364d-8d37-f3cb72866470",
      "content": {
        "id": "6b01c7dd-5955-364d-8d37-f3cb72866470",
        "contentType": "VIDEO",
        "title": "Apple & Amazon earnings, Fed, mortgage rates: What to Watch",
        "description": "<p>Market Domination Overtime host <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/josh-lipton/\">Josh Lipton</a> previews several of the biggest stories to come tomorrow, Thursday, October 30, including earnings results from Big Tech names Apple (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/AAPL\">AAPL</a>) and Amazon (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/AMZN\">AMZN</a>), commentary from the Federal Reserve's Michelle Bowman, and the latest mortgage rates reading.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out moreÂ <a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-domination-overtime/\">Market Domination Overtime</a>.</p>",
        "summary": "Market Domination Overtime host Josh Lipton previews several of the biggest stories to come tomorrow, Thursday, October 30, including earnings results from Big Tech names Apple (AAPL) and Amazon (AMZN), commentary from the Federal Reserve's Michelle Bowman, and the latest mortgage rates reading. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Domination Overtime.",
        "pubDate": "2025-10-29T23:00:00Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-10/3f4d91f0-b4f9-11f0-97f2-4d904ec286a4",
          "originalWidth": 1920,
          "originalHeight": 1080,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ddxWUTs5nTIRnkMY2nVuPQ--~B/aD0xMDgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-10/3f4d91f0-b4f9-11f0-97f2-4d904ec286a4.cf.webp",
              "width": 1920,
              "height": 1080,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ybngvkhmingWw9hDkOGuqg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-10/3f4d91f0-b4f9-11f0-97f2-4d904ec286a4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/apple-amazon-earnings-fed-mortgage-230000928.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/apple-amazon-earnings-fed-mortgage-230000928.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MA"
            },
            {
              "symbol": "CMCSA"
            },
            {
              "symbol": "AMZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T12:58:00+00:00",
    "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?",
    "summary": "Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.",
    "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-125800909.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f6af8322-e0a1-30fd-ad58-b5698007d947",
      "content": {
        "id": "f6af8322-e0a1-30fd-ad58-b5698007d947",
        "contentType": "STORY",
        "title": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?",
        "description": "",
        "summary": "Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.",
        "pubDate": "2025-10-29T12:58:00Z",
        "displayTime": "2025-10-29T12:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Rsglp9DcmN3_7BlBHZoXjg--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uDSo4QJoyaPL6uIXq9MpVA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-125800909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-125800909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T11:00:00+00:00",
    "headline": "Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma",
    "summary": "RAHWAY, N.J. & NUTLEY, N.J., October 29, 2025--Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma",
    "url": "https://finance.yahoo.com/news/merck-eisai-phase-3-leap-110000207.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "48786d5b-9f7f-3bd0-a8a9-7aa1b22f2212",
      "content": {
        "id": "48786d5b-9f7f-3bd0-a8a9-7aa1b22f2212",
        "contentType": "STORY",
        "title": "Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma",
        "description": "",
        "summary": "RAHWAY, N.J. & NUTLEY, N.J., October 29, 2025--Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma",
        "pubDate": "2025-10-29T11:00:00Z",
        "displayTime": "2025-10-29T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/910de16fd9da24bc23a005bc635efa6c",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VhmNzmkChEjM5JZPzAIrqA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/910de16fd9da24bc23a005bc635efa6c.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4TtZ3GmZ_Xj.OZXsKaDEIQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/910de16fd9da24bc23a005bc635efa6c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-eisai-phase-3-leap-110000207.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-eisai-phase-3-leap-110000207.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "4523.T"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T10:45:00+00:00",
    "headline": "European Commission Approves KEYTRUDAÂ® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)",
    "summary": "RAHWAY, N.J., October 29, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDAÂ® (pembrolizumab), Merckâs anti-PD-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adul",
    "url": "https://finance.yahoo.com/news/european-commission-approves-keytruda-pembrolizumab-104500983.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "452bb2ff-258e-3b3f-8f5d-81dc6493e514",
      "content": {
        "id": "452bb2ff-258e-3b3f-8f5d-81dc6493e514",
        "contentType": "STORY",
        "title": "European Commission Approves KEYTRUDAÂ® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)",
        "description": "",
        "summary": "RAHWAY, N.J., October 29, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDAÂ® (pembrolizumab), Merckâs anti-PD-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adul",
        "pubDate": "2025-10-29T10:45:00Z",
        "displayTime": "2025-10-29T10:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/03d796e4a38e8541627ace53344f8c22",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cFuZEMMKQvBsF5wZQIvAzg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/03d796e4a38e8541627ace53344f8c22.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U5wjhR4lwJ2unGhof82vIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/03d796e4a38e8541627ace53344f8c22.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/european-commission-approves-keytruda-pembrolizumab-104500983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/european-commission-approves-keytruda-pembrolizumab-104500983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T03:16:15+00:00",
    "headline": "Merck (MRK) Reports Earnings Tomorrow: What To Expect",
    "summary": "Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Hereâs what you need to know.",
    "url": "https://finance.yahoo.com/news/merck-mrk-reports-earnings-tomorrow-031615955.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "99c0a5fb-3850-3c96-a1e4-85207df32019",
      "content": {
        "id": "99c0a5fb-3850-3c96-a1e4-85207df32019",
        "contentType": "STORY",
        "title": "Merck (MRK) Reports Earnings Tomorrow: What To Expect",
        "description": "",
        "summary": "Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Hereâs what you need to know.",
        "pubDate": "2025-10-29T03:16:15Z",
        "displayTime": "2025-10-29T03:16:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/ebe2be3c9f70cfc1092fc0a56a0c75dc",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "MRK Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PqkkAVnP2lidjvyb58UUUQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/ebe2be3c9f70cfc1092fc0a56a0c75dc.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jUpD9l9St2LHULbO70D5fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/ebe2be3c9f70cfc1092fc0a56a0c75dc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-reports-earnings-tomorrow-031615955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-reports-earnings-tomorrow-031615955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]